JW Asset Management

Jason Wild is the sole portfolio manager and decision-maker. He founded the firm and directs all investment activity across public equities, private placements, and structured credit. Wild is a licensed pharmacist, and his clinical training informs the firm's heavy biotech and specialty pharma exposure.

JW Asset Management is TerrAscend's largest shareholder, and Jason Wild serves as Executive Chairman of the cannabis multi-state operator. Wild stepped into the chairman role to directly oversee strategy, regulatory licensing, and operational execution. The position reflects JW's broader model of taking hands-on board roles in portfolio companies.

JW Asset Management is registered as an investment adviser and functions as the investment vehicle for Jason Wild, though the firm's precise mix of proprietary versus external capital is not publicly detailed. The structure bears similarities to a single-family-office model in its concentration and permanent-capital patience, but operates under an RIA registration in New York.

JW has not published an explicit exclusion list. The portfolio's observable concentration in biotech, specialty pharma, cannabis, and select consumer situations implies it does not prioritize sectors where the team lacks clinical, regulatory, or operational expertise. Large-cap passive exposure, commodity cyclicals, and traditional energy names are absent from known filings.

Wild earned his pharmacy degree before entering investing, and his clinical training provides the analytical lens for JW's biotech and pharma positions. He evaluates pipeline assets, FDA regulatory pathways, and reimbursement dynamics with a clinician's understanding of how drugs reach patients. This domain fluency is the firm's primary analytical edge in healthcare investing.